1. Goadsby, PJ, Edvinsson, L, Ekman, R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183–187.
Google Scholar | Crossref | Medline | ISI2. Villalón, CM, Olesen, J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther 2009; 124: 309–323.
Google Scholar | Crossref | Medline | ISI3. Raffaelli, B, Neeb, L, Reuter, U. Monoclonal antibodies for the prevention of migraine. Exp Opin Bio Ther 2019; 12: 1307–1317.
Google Scholar | Crossref | Medline4. Kanaan, S, Hettie, G, Loder, E, et al. Real-world effectiveness and tolerability of erenumab: A retrospective cohort study. Cephalalgia 2020; 40: 1511–1522.
Google Scholar | SAGE Journals | ISI5. Alex, A, Vaughn, C, Rayhill, M. Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study. Headache 2020; 60: 2454–2462.
Google Scholar | Crossref | Medline6. Ziegeler, C, May, A. Non-responders to treatment with antibodies to the CGRP-receptor may profit from a switch of antibody class. Headache 2020; 60: 469–470.
Google Scholar | Crossref | Medline7. Hepp, Z, Dodick, DW, Varon, SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. Cephalalgia 2017; 37: 470–485.
Google Scholar | SAGE Journals | ISI8. Olesen, J. International Classification of Headache Disorders. Lancet Neurol 2018; 17: 396–397.
Google Scholar | Crossref | Medline9. Diener HC, Gaul C, Kropp P, et al. Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie, 2018. In: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Available at: https://dgn.org/leitlinien/ll-030-057-2018-therapie-der-migraeneattacke-und-prophylaxe-der-migraene (accessed 03 March 2021).
Google Scholar10. Sacco, S, Braschinsky, M, Ducros, A, et al. European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 2020; 21: 76.
Google Scholar | Crossref | Medline11. Silberstein, S, Tfelt-Hansen, P, Dodick, DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008; 28: 484–495.
Google Scholar | SAGE Journals | ISI12. National Institute for Health and Care Excellence. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. 2012. Available at: https://www.nice.org.uk/guidance/ta260 (accessed 03 March 2021).
Google Scholar13. Ruscheweyh, R, Förderreuther, S, Gaul, C, et al. Treatment of chronic migraine with botulinum neurotoxin A: Expert recommendations of the German Migraine and Headache Society. Nervenarzt 2018; 89: 1355–1364.
Google Scholar | Crossref | Medline14. Tajti, J, Szok, D, Majláth, Z, et al. Migraine and neuropeptides. Neuropeptides 2015; 52: 19–30.
Google Scholar | Crossref | Medline | ISI15. Cernuda-Morollon, E, Ramon, C, Martinez-Camblor, P, et al. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain 2015; 156: 820–824.
Google Scholar | Crossref | Medline | ISI16. Cernuda-Morollon, E, Martinez-Camblor, P, Ramon, C, et al. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache 2014; 54: 987–995.
Google Scholar | Crossref | Medline | ISI17. Edvinsson, L, Grell, A-S, Warfvinge, K. Expression of the CGRP family of neuropeptides and their receptors in the trigeminal ganglion. J Molecular Neurosci 2020; 70: 930–944.
Google Scholar | Crossref | Medline18. Edvinsson, L, Haanes, KA, Warfvinge, K, et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 2018; 14: 338–350.
Google Scholar | Crossref | Medline19. Ferrari, MD, Diener, HC, Ning, X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 2019; 394: 1030–1040.
Google Scholar | Crossref | Medline20. Mulleners, WM, Kim, BK, Láinez, MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2020; 19: 814–825.
Google Scholar | Crossref | Medline21. Reuter, U, Goadsby, PJ, Lanteri-Minet, M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 2018; 392: 2280–2287.
Google Scholar | Crossref | Medline22. Raffaelli, B, Kalantzis, R, Mecklenburg, J, et al. Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxina: a dual-center retrospective observational study. Front Neurol 2020; 11: 417.
Google Scholar | Crossref | Medline23. Scheffler, A, Messel, O, Wurthmann, S, et al. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence. J Headache Pain 2020; 21: 84.
Google Scholar | Crossref | Medline24. Ornello, R, Casalena, A, Frattale, I, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 2020; 21: 32.
Google Scholar | Crossref | Medline25. Lambru, G, Hill, B, Murphy, M, et al. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 2020; 21: 61.
Google Scholar | Crossref | Medline26. Russo, A, Silvestro, M, Scotto di Clemente, F, et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain 2020; 21: 69.
Google Scholar | Crossref | Medline27. Dodick, DW, Doty, EG, Aurora, SK, et al. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia 2021; 41: 340–352.
Google Scholar | SAGE Journals | ISI28. Tepper, SJ, Diener, HC, Ashina, M, et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology 2019; 92: e2309–e2320.
Google Scholar | Crossref | Medline29. Diener, HC, Schorn, CF, Bingel, U, et al. The importance of placebo in headache research. Cephalalgia 2008; 28: 1003–1011.
Google Scholar | SAGE Journals | ISI30. Ashina, M, Tepper, S, Brandes, JL, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 2018; 38: 1611–1621.
Google Scholar | SAGE Journals | ISI